The approval paves the way for drugs designed to remove harmful proteins from cells, rather than simply block them. This is an advance because these drugs, called PROTACs, can sidestep the barriers to treating diseases that involve hitherto ‘undruggable’ proteins. Researchers have been developing this technology for over two decades
